Etanercept | Infliximab | Adalimumab | |||||||
---|---|---|---|---|---|---|---|---|---|
Reason for Discontinuation | Reason for Discontinuation | Reason for Discontinuation | |||||||
Variable | Any | Adverse Events | Inefficacy | Any | Adverse Events | Inefficacy | Any | Adverse Events | Inefficacy |
Demographic variables | |||||||||
Age | 1.00 (0.99–1.01) p = 0.924 | 0.99 (0.97–1.01) p = 0.461 | 1.00 (0.98–1.02) p = 0.861 | 0.99 (0.98–1.00) p = 0.002 | 1.00 (0.99–1.01) p = 0.383 | 0.98 (0.96–0.99) p < 0.0001 | 1.00 (0.98–1.02) p = 0.926 | 1.01 (0.98–1.05) p = 0.481 | 0.99 (0.96–1.01) p = 0.341 |
Female sex | 1.30 (0.95–1.78) p = 0.101 | 2.27 (1.03–4.98) p = 0.041 | 1.22 (0.71–2.10) p = 0.480 | 1.24 (1.01–1.51) p = 0.040 | 1.23 (0.88–1.71) p = 0.231 | 1.26 (0.85–1.86) p = 0.256 | 1.08 (0.70–1.64) p = 0.738 | 3.06 (0.93–10.06) p = 0.066 | 0.68 (0.35–1.32) p = 0.257 |
White | 0.71 (0.52–0.97) p = 0.033 | 0.84 (0.43–1.64) p = 0.602 | 0.62 (0.36–1.05) p = 0.073 | 0.85 (0.69–1.04) p = 0.109 | 0.89 (0.63–1.25) p = 0.485 | 0.94 (0.62–1.43) p = 0.773 | 1.34 (0.79–2.26) p = 0.280 | 1.89 (0.57–6.23) p = 0.295 | 3.93 (0.95–16.3) p = 0.059 |
No. comorbidities | 1.21 (1.00–1.47) p = 0.045 | 1.28 (0.88–1.86) p = 0.203 | 1.16 (0.82–1.64) p = 0.395 | 1.06 (0.94–1.19) p = 0.350 | 1.24 (1.04–1.48) p = 0.017 | 0.99 (0.78–1.27) p = 0.953 | 1.15 (0.86–1.55) p = 0.340 | 1.32 (0.77–2.26) p = 0.319 | 1.28 (0.79–2.06) p = 0.312 |
Disease variables | |||||||||
Disease severity (CDAI > 22) | 1.10 (0.83–1.46) p = 0.511 | 0.98 (0.56–1.74) p = 0.955 | 1.55 (0.89–2.72) p = 0.123 | 1.35 (1.08–1.69) p = 0.009 | 1.36 (0.94–1.98) p = 0.102 | 1.82 (1.12–2.94) p = 0.015 | 1.21 (0.79–1.85) p = 0.372 | 1.93 (0.74–5.02) p = 0.179 | 0.88 (0.45–1.73) p = 0.708 |
Disease duration | 1.00 (0.98–1.01) p = 0.629 | 1.01 (0.98–1.04) p = 0.605 | 0.97 (0.94–1.00) p = 0.065 | 1.00 (0.99–1.01) p = 0.949 | 1.01 (1.00–1.02) p = 0.105 | 0.98 (0.97–1.00) p = 0.058 | 1.01 (0.99–1.03) p = 0.430 | 1.00 (0.97–1.04) p = 0.898 | 1.00 (0.97–1.04) p = 0.837 |
Medicare | 1.30 (0.95–1.77) p = 0.104 | 1.10 (0.56–2.16) p = 0.786 | 1.39 (0.81–2.40) p = 0.233 | 0.89 (0.76–1.05) p = 0.175 | 1.10 (0.84–1.45) p = 0.475 | 0.71 (0.51–1.00) p = 0.050 | 1.07 (0.71–1.59) p = 0.757 | 1.53 (0.73–3.20) p = 0.257 | 0.82 (0.39–1.71) p = 0.590 |
Employment status (employed) | 0.94 (0.74–1.21) p = 0.636 | 1.05 (0.63–1.76) p = 0.848 | 0.95 (0.61–1.47) p = 0.821 | 1.13 (0.96–1.34) p = 0.139 | 1.10 (0.83–1.45) p = 0.510 | 1.28 (0.93–1.77) p = 0.137 | 1.15 (0.80–1.65) p = 0.459 | 0.83 (0.40–1.72) p = 0.620 | 1.91 (0.99–3.68) p = 0.054 |
Rheumatoid factor-positive | 1.35 (0.98–1.86) p = 0.067 | 0.93 (0.52–1.67) p = 0.811 | 1.58 (0.87–2.86) p = 0.134 | 0.97 (0.79–1.19) p = 0.750 | 1.12 (0.79–1.60) p = 0.525 | 0.87 (0.59–1.28) p = 0.483 | 0.82 (0.52–1.27) p = 0.371 | 1.03 (0.39–2.71) p = 0.960 | 0.75 (0.35–1.59) p = 0.454 |
Prednisone use at baseline | 1.06 (0.84–1.35) p = 0.619 | 0.76 (0.46–1.24) p = 0.272 | 1.26 (0.81–1.94) p = 0.304 | 1.12 (0.95–1.32) p = 0.185 | 1.12 (0.85–1.48) p = 0.419 | 1.21 (0.87–1.68) p = 0.255 | 1.26 (0.87–1.82) p = 0.228 | 1.60 (0.75–3.39) p = 0.225 | 1.11 (0.59–2.09) p = 0.750 |
HAQ > 0.5 | 1.28 (0.93–1.76) p = 0.134 | 1.08 (0.58–2.03) p = 0.809 | 0.96 (0.57–1.62) p = 0.880 | 0.88 (0.70–1.11) p = 0.280 | 0.81 (0.56–1.18) p = 0.271 | 1.03 (0.64–1.67) p = 0.901 | 1.08 (0.68–1.74) p = 0.740 | 2.21 (0.67–7.28) p = 0.193 | 0.77 (0.37–1.62) p = 0.488 |
CDAI: Clinical Disease Activity Index; HAQ: Health Assessment Questionnaire.